Plain-English translation of NCT05578326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing paired with , an existing cancer medication, for people with advanced small cell lung cancer whose disease progressed after standard first-line chemotherapy. Researchers want to see if adding can reduce the serious blood-related side effects that often happen with alone, and whether the combination works better together to fight the cancer.
Standard treatments for advanced small cell lung cancer only keep the disease under control for about 4 months before it comes back. When cancer progresses after initial treatment, there aren't clear guidelines on what to do next. This study is trying to find a safer, more effective way to treat patients at this stage by pairing this medication with a drug that may protect bone marrow from damage.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination ( and ) as part of your cancer treatment plan. The study involves visits to the research center where your doctors will monitor how well the treatment is working and track any side effects through blood tests and imaging scans. Your participation will help researchers understand whether this combination is safer and more effective than alone for people like you with advanced lung cancer.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States